BioNTech (BNTX) shares experienced a slight decline amid market activity focused on cancer vaccine developments.
BioNTech SE's stock moved down by 1.16% on October 10, 2026, closing at US$90.26. This movement comes as the market reacts to broader developments in the vaccine sector, particularly regarding U.S.-led initiatives for cancer vaccines. Over the past week, BioNTech's shares have declined 1.84%, and they are down 0.92% over the last month, reflecting ongoing challenges in the market.
Advertisement
BioNTech SE
BNTX.US
BNTX.US
BioNTech SE
WealthAwesomeMarket cap
$24.36B
52W high
$124.00
52W low
$79.52
1W change
-1.84%
Beta
1.25
Analyst Price Targets
Based on 21 analysts covering BNTX · as of Oct 12, 2026
Wall Street analysts forecast BNTX stock price to rise 21.3% over the next 12 months.
Consensus
Buy4.24 / 5.00
Avg. Target
C$116.21
+21.3% Upside
Previously C$116.54 on Oct 9, 2026
Current Price
C$95.84
Last close
Analyst Breakdown (21 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BNTX's historical volatility
30-Day Vol
33.1%
Annualized
90-Day Vol
47.3%
Annualized
Trend (90d)
+19.6%
Annualized drift
90d Mean
C$102.77
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$98.10 | C$87.53 – C$109.95 |
| 60 trading days | C$100.41 | C$85.45 – C$117.98 |
| 90 trading days | C$102.77 | C$84.35 – C$125.22 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should monitor ongoing developments in the vaccine market that may impact BioNTech's future performance.
BioNTech's Stock Declines with 1.40x Volume Surge
The latest trading volume of 1,032,678 shares exceeded the 20-day average by 40%, indicating heightened trading activity despite the stock's decline.
Bull case
Analysts are optimistic about BioNTech, with an average target price suggesting a potential upside of 28.8% from the last close. This positive outlook reflects confidence in the company's future prospects, particularly as developments in the cancer vaccine space unfold.
Bear case
However, concerns remain due to the company's negative profit margins and declining stock performance, which could worry investors. These factors may lead to increased scrutiny of BioNTech's financial health and market position.
BioNTech's Stock Movement
Advertisement
On October 10, 2026, BioNTech SE's stock decreased by 1.16%, closing at US$90.26. This decline is part of a broader trend, with shares down 1.84% over the past week and 0.92% in the last month. Year-to-date, the stock has also seen a decrease of 0.88%. The trading volume for the day was 1,032,678 shares, significantly higher than the 20-day average of 898,710 shares, indicating increased investor activity.
Market Context and Trading Volume
The stock's latest volume represents a 1.40 times increase over the 20-day average, suggesting that investors are actively reacting to news surrounding the vaccine sector. BioNTech's stock is currently trading approximately 8.7% below its 50-day moving average of US$98.90 and 7.7% below its 200-day moving average of US$97.79. Additionally, the stock is within 24% of its 52-week range of US$79.52 to US$124.00, reflecting its volatility in the current market.
Future Implications for BioNTech
Looking ahead, investors are advised to keep an eye on developments regarding cancer vaccine initiatives, as these could significantly impact BioNTech's market position. Analysts maintain an average target price of US$116.21 for the stock, suggesting a potential upside of 28.8% from its last closing price. Despite the current challenges, the company's market capitalization stands at approximately US$24.36 billion, indicating a substantial valuation, albeit with a profit margin of -63.6% and a return on equity of -9.3%.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
